Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT05065411

Public ClinicalTrials.gov record NCT05065411. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

P3 Efficacy Evaluation of Enobosarm in Combo With Abemaciclib Compared to Estrogen Blocking Agent for 2nd Line Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent Plus Palbociclib

Study identification

NCT ID
NCT05065411
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Veru Inc.
Industry
Enrollment
5 participants

Conditions and interventions

Interventions

  • Enobosarm & Abemaciclib Combo Drug
  • non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 10, 2022
Primary completion
Oct 18, 2023
Completion
Jan 8, 2024
Last update posted
Feb 25, 2024

2022 – 2024

United States locations

U.S. sites
30
U.S. states
16
U.S. cities
29
Facility City State ZIP Site status
Ironwood Cancer & Research Centers Chandler Arizona 85224
Banner MDACC Gilbert Arizona 85234
Arizona Oncology Associates, PC-HOPE Tucson Arizona 85711
Los Angeles Cancer Network One Oncology Los Angeles California 90017
UCLA Parkside Cancer Center Los Angeles California 90095
Sharp Center for Research San Diego California 92123
Sansum Clinic, CA Santa Barbara California 93105
Innovative Clinical Research Institute Whittier California 90603
Med OncologyHematology Consultants, PA Newark Newark Delaware 19713-7007
Lakes Research Miami Lakes Florida 33014
Maryland Oncology Hematology, P.A. Annapolis Maryland 21401
Baystate Regional Cancer Program - D'Amour Center for Cancer Care Springfield Massachusetts 01199-1005
University of Mississippi Medical Center Jackson Mississippi 39213
Washington University St. Louis St Louis Missouri 63110
Renown Health Reno Nevada 89502
Summit Medical Group, Florham Park Campus Florham Park New Jersey 07932-1049
The New York Hospital Westbury New York 11590
The Lindner Center for Research and Education at the Christ Hospital Cincinnati Ohio 45219
Toledo Clinic Cancer Centers - Main Office Toledo Ohio 43623
UPMC Magee-Women's Hospital Pittsburgh Pennsylvania 15219
Texas Oncology, PA Dallas Texas 75246
Texas Oncology, PA Denton Texas 76201
Texas Oncology, P.A. El Paso Texas 79902
Texas Oncology, P.A. Flower Mound Texas 75028
UT MD Anderson CC Houston Texas 77030
Texas Oncology, P.A. San Antonio Texas 78240
Texas Oncology, P.A. Tyler Texas 75702
Virginia Oncology Assoc Norfolk Virginia 23502
University of Washington Seattle Cancer Center Alliance (SCCA) Seattle Washington 98109-1023
Cancer Care Northwest Spokane Washington 99216

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05065411, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 25, 2024 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05065411 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →